CLINICAL IMPACT OF SECOND-GENERATION EVEROLIMUS-ELUTING STENTS COMPARED WITH FIRST-GENERATION DRUG-ELUTING STENTS IN DIABETIC PATIENTS UNDERGOING MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Clinical Impact of Second-Generation Everolimus- Eluting Stent Compared With First-Generation Drug-Eluting Stents in Diabetes Mellitus Patients

Results In 4,751 percutaneous coronary intervention-treated DM patients, 8,134 stents were implanted (EES 3,928, PES 2,836, SES 1,370). The EES was associated with significantly lower event rates compared with SES (SES vs. EES hazard ratio [HR]: 1.99; 95% confidence interval (CI): 1.19 to 3.08). The same was observed when compared with PES (PES vs. EES HR: 1.33; 95% CI: 0.93 to 1.91) but did no...

متن کامل

one-year outcome of everolimus-eluting stents versus biolimus-eluting stents in patients undergoing percutaneous coronary intervention

background: the biolimus-eluting stent (bes), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (ees), as a second-generation drug-eluting stent (des).we sought to compare the 1-year outcome between the promus ™ stent (ees type) and the biomatrix ™ stent (bes type). methods: from march 2008 to september 2011, all patients treated with the promus™ s...

متن کامل

Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Kyung Woo Park, MD,* In-Ho Chae, MD,† Do-Sun Lim, MD,‡ Kyoo-Rok Han, MD,§ Han-Mo Yang, MD,* Hae-Young Lee, MD,* Hyun-Jae Kang, MD,* Bon-Kwon Koo, MD,* Taehoon Ahn, MD, Jung-Han Yoon, MD,¶ Myung-Ho Jeong, MD,# Taek-Jong Hong, MD,** Woo-Young Chung, MD,†† Sang-Ho Jo, MD,‡‡ Young-Jin Choi, MD,‡‡ Seung-Ho Hur, MD,§§ Hyuck-Moon Kwon, MD, Dong-Woon Jeon, MD,¶¶ Byung-Ok Kim, MD,## Si-Hoon Park, MD,***...

متن کامل

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Background: The biolimus-eluting stent (BES), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (EES), as a second-generation drug-eluting stent (DES).We sought to compare the 1-year outcome between the PROMUS™ stent (EES type) and the BioMatrix™ stent (BES type). Methods: From March 2008 to September 2011, all patients treated with the PROMUS™ ste...

متن کامل

Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.

BACKGROUND Clinical trials have demonstrated that the second-generation cobalt-chromium everolimus-eluting stent (CoCr-EES) is superior to the first-generation paclitaxel-eluting stent (PES) and is noninferior or superior to the sirolimus-eluting stent (SES) in terms of safety and efficacy. It remains unclear whether vascular responses to CoCr-EES are different from those to SES and PES because...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of the American College of Cardiology

سال: 2014

ISSN: 0735-1097

DOI: 10.1016/s0735-1097(14)61912-4